Evaluation of effectiveness of treatment of chronic hepatitis C in real life in retrospective and prospective studies: management trials, development plans, data analysis and socio-economic approaches

• Grant number: 14/00058-1
• Support Opportunities: Scholarships abroad - Research
• Start date: June 01, 2014
• End date: July 31, 2014
• Field of knowledge: Health Sciences - Collective Health - Epidemiology
• Principal Investigator: Norma Suely de Oliveira Farias
• Grantee: Norma Suely de Oliveira Farias
• Host Investigator: Fabrice Carrat
• Host Institution: Centro de Vigilância Epidemiológica Alexandre Vranjac (CVE). Coordenadoria de Controle de Doenças (CCD). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil
• Institution abroad: Institut National de la Santé et de la Recherche Médicale (Inserm), France

Abstract

The goal of the project research fellowship abroad is to incorporate methodological knowledge in the organization and management aimed at evaluating the effectiveness of treatment of hepatitis C (HCV) in conditions of real life trials and further scientific collaboration with the Agence Nationale de Recherche sur le Sida et les Hépatites Virales - ANRS and INSERM, France. Since the late 90s, the Secretary of Health of São Paulo (SES - SP) and the Health Ministry in line with the international literature have established protocols to treat chronic hepatitis C (HCV). Several studies evaluating the effectiveness of alfapeguinterferona and ribavirin in terms of "real life" conducted in other countries have shown similar responses to those reported in clinical trials phase 3. Design Retrospective cohort study supported by the Research Support Foundation of the State of São Paulo - FAPESP is currently under development in the State of São Paulo , coordinated by the Institute of Tropical Medicine of the USP (researcher in charge) and in collaboration with the Centre Epidemiological Surveillance of SES/SP, which participate as principal investigator, supported the hypothesis that the establishment of a network of care in attention to drug treatment of patients with HCV may have a positive impact on adherence and management of adverse events, contributing best to achieve sustained virologic response. Until then, there was no publications in the literature that evaluate the effectiveness of treatment of HCV in the country, comparing the SVR with the effectiveness of clinical trials, objective specific of this research. The research project to be developed in the research fellowship abroad program may help to deepen the experience that I have been accumulating in the investigation of the effectiveness of treatment of HCV and for the implementation of prospective cohort study aimed at assessing the effectiveness of new drugs in treatment of HCV, such as protease inhibitors, and in view of the ongoing review of the care network services. (AU)